172 related articles for article (PubMed ID: 37232824)
1. Outcomes of a Multidisciplinary Team in the Management of Patients with Early-Stage Breast Cancer Undergoing Neoadjuvant Chemotherapy at a Community Cancer Center.
Bhardwaj PV; Mason H; Kaufman SA; Visintainer P; Makari-Judson G
Curr Oncol; 2023 May; 30(5):4861-4870. PubMed ID: 37232824
[No Abstract] [Full Text] [Related]
2. Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study.
Zeidman M; Alberty-Oller JJ; Ru M; Pisapati KV; Moshier E; Ahn S; Mazumdar M; Port E; Schmidt H
Breast Cancer Res Treat; 2020 Nov; 184(1):203-212. PubMed ID: 32740807
[TBL] [Abstract][Full Text] [Related]
3. National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study.
Puig CA; Hoskin TL; Day CN; Habermann EB; Boughey JC
Ann Surg Oncol; 2017 May; 24(5):1242-1250. PubMed ID: 28000076
[TBL] [Abstract][Full Text] [Related]
4. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment.
Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC
BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
7. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy.
Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML
Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Lymphovenous Anastomosis in Clinically Node-Positive Women Receiving Neoadjuvant Chemotherapy: A Shared Decision-Making Model and Nuanced Approached to the Axilla.
Lustig DB; Temple-Oberle C; Bouchard-Fortier A; Quan ML
Curr Oncol; 2023 Apr; 30(4):4041-4051. PubMed ID: 37185419
[TBL] [Abstract][Full Text] [Related]
9. Management of the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: A single-center study.
Aksoy SO; Sevinc Aİ; Ünal M; Balci P; Görkem İB; Durak MG; Ozer O; Bekiş R; Emir B
Medicine (Baltimore); 2020 Dec; 99(49):e23538. PubMed ID: 33285770
[TBL] [Abstract][Full Text] [Related]
10. Assessing the impact of neoadjuvant chemotherapy on the management of the breast and axilla in breast cancer.
McVeigh TP; Al-Azawi D; Kearney DE; Malone C; Sweeney KJ; Barry K; McLaughlin R; Keane M; Kerin MJ
Clin Breast Cancer; 2014 Feb; 14(1):20-5. PubMed ID: 24157259
[TBL] [Abstract][Full Text] [Related]
11. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.
Spronk PER; van Bommel ACM; Siesling S; Wouters MWJM; Vrancken Peeters MTFD; Smorenburg CH
Breast; 2017 Dec; 36():34-38. PubMed ID: 28942098
[TBL] [Abstract][Full Text] [Related]
12. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
[TBL] [Abstract][Full Text] [Related]
13. Management of the axilla following neoadjuvant chemotherapy for breast cancer- A change in practice.
Riogi B; Sripadam R; Barker D; Harris O; Innes H; Chagla L
Surgeon; 2021 Feb; 19(1):1-7. PubMed ID: 32192932
[TBL] [Abstract][Full Text] [Related]
14. Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?
Barrio AV; Mamtani A; Eaton A; Brennan S; Stempel M; Morrow M
Ann Surg Oncol; 2017 Mar; 24(3):645-651. PubMed ID: 28130619
[TBL] [Abstract][Full Text] [Related]
15. MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
Weber JJ; Jochelson MS; Eaton A; Zabor EC; Barrio AV; Gemignani ML; Pilewskie M; Van Zee KJ; Morrow M; El-Tamer M
J Am Coll Surg; 2017 Dec; 225(6):740-746. PubMed ID: 28919579
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
17. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
[TBL] [Abstract][Full Text] [Related]
18. Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.
Takahashi M; Jinno H; Hayashida T; Sakata M; Asakura K; Kitagawa Y
World J Surg; 2012 Dec; 36(12):2847-52. PubMed ID: 22806206
[TBL] [Abstract][Full Text] [Related]
19. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
20. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.
Diego EJ; McAuliffe PF; Soran A; McGuire KP; Johnson RR; Bonaventura M; Ahrendt GM
Ann Surg Oncol; 2016 May; 23(5):1549-53. PubMed ID: 26727919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
